ANIP: ANI Pharmaceuticals, Inc. - Summary | Jitta

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Price
$58.19
Loss Chance
53.8%
2.98JITTA SCORE
137.16%Over Jitta Line
Jitta Ranking
183 / 1,156
1,903 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (59)
Recent Business Performance (67)
Financial Strength (51)
Return to Shareholders (7)
Competitive Advantage (45)
Jitta Signs
Revenue and EarningEarning loss detected in 2022
Operating MarginInconsistent
Recent Business PerformanceEarning decline 117.02% in the last year
SG&A to SalesIncreasing Every Year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
2.98
137.16%
1.98
169.91%
2.00
168.87%
Pharmaceuticals
2.62
93.04%
6.63
36.25%
4.26
83.54%
COMPANY DESCRIPTION
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.